Compare ZM & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZM | RMD |
|---|---|---|
| Founded | 2011 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0B | 33.6B |
| IPO Year | 2019 | 1996 |
| Metric | ZM | RMD |
|---|---|---|
| Price | $81.63 | $235.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 20 |
| Target Price | $118.52 | ★ $264.33 |
| AVG Volume (30 Days) | ★ 2.6M | 1.3M |
| Earning Date | 11-23-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 1.11% |
| EPS Growth | ★ 92.52 | 9.67 |
| EPS | ★ 6.56 | 2.92 |
| Revenue | ★ $4,868,769,000.00 | $2,957,013,000.00 |
| Revenue This Year | $4.60 | $3.12 |
| Revenue Next Year | $4.46 | $6.43 |
| P/E Ratio | ★ $12.78 | $81.12 |
| Revenue Growth | 4.36 | ★ 13.44 |
| 52 Week Low | $70.70 | $180.27 |
| 52 Week High | $114.74 | $277.67 |
| Indicator | ZM | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | 47.95 |
| Support Level | $77.02 | $218.45 |
| Resistance Level | $93.34 | $242.40 |
| Average True Range (ATR) | 4.53 | 7.20 |
| MACD | -1.19 | -0.60 |
| Stochastic Oscillator | 5.08 | 57.31 |
Zoom Communications provides a video-first communications platform that connects people through frictionless video, voice, chat, and content sharing. The company's cloud-native platform enables video experiences and connects users across various devices and locations in a single meeting. Zoom has launched a variety of communications-related solutions, including Zoom Phone and Zoom Contact Center. The firm was founded in 2011 and serves companies of all sizes from all industries around the world.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.